RPMI-1788/Cre cells are derived from the human B lymphocyte RPMI-1788 cell line by stably integration of a constitutive Cre recombinase stably expression construct. RPMI-1788 cells have been used in cancer research and drug development. RPMI-1788/Cre cells stably express a nuclear localized Cre recombinase under the control of a CMV promoter.